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Abstract
Background:  Phosphatase of regenerating liver-3 (PRL-3) plays a causative role in tumor
metastasis, but the underlying mechanisms are not well understood. In our previous study, we
observed that PRL-3 could decrease tyrosine phosphorylation of integrin β1 and enhance activation
of ERK1/2 in HEK293 cells. Herein we aim to explore the association of PRL-3 with integrin β1
signaling and its functional implications in motility, invasion, and metastasis of colon cancer cell
LoVo.
Methods: Transwell chamber assay and nude mouse model were used to study motility and
invasion, and metastsis of LoVo colon cancer cells, respectively. Knockdown of integrin β1 by
siRNA or lentivirus were detected with Western blot and RT-PCR. The effect of PRL-3 on integrin
β1, ERK1/2, and MMPs that mediate motility, invasion, and metastasis were measured by Western
blot, immunofluorencence, co-immunoprecipitation and zymographic assays.
Results:  We demonstrated that PRL-3 associated with integrin β1 and its expression was
positively correlated with ERK1/2 phosphorylation in colon cancer tissues. Depletion of integrin β1
with siRNA, not only abrogated the activation of ERK1/2 stimulated by PRL-3, but also abolished
PRL-3-induced motility and invasion of LoVo cells in vitro. Similarly, inhibition of ERK1/2
phosphorylation with U0126 or MMP activity with GM6001 also impaired PRL-3-induced invasion.
In addition, PRL-3 promoted gelatinolytic activity of MMP2, and this stimulation correlated with
decreased TIMP2 expression. Moreover, PRL-3-stimulated lung metastasis of LoVo cells in a nude
mouse model was inhibited when integrin β1 expression was interfered with shRNA.
Conclusion: Our results suggest that PRL-3's roles in motility, invasion, and metastasis in colon
cancer are critically controlled by the integrin β1-ERK1/2-MMP2 signaling.
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Background
Colorectal cancer ranks third in the incidence of cancer in
the world, and metastasis is the main death cause.
Although causes and genetic bases of tumorigenesis vary
greatly, key events required for metastasis are similar,
including alteration of adhesion ability, enhancement of
motility, and secretion of proteolytic enzymes to degrade
extracellular matrix (ECM) and vascular basement mem-
brane; all these steps are orchestrated by a plethora of sig-
naling events. Phosphatase of regenerating liver-3 (PRL-
3), also known as PTP4A3, encodes a 22-kilodalton pro-
tein tyrosine phosphatase and is characteristic of a CAAX
motif for prenylation at the carboxyl terminus [1]. At
mRNA level, it is detected primarily in skeletal and cardiac
muscles, somewhat in pancreas, but rarely in brain, lungs,
liver, kidneys, and placenta [2]. However, it is highly
expressed in multiple cancer cell lines and vascular
endothelial cells [3-5]. Initially, PRL-3 was found to be
up-regulated in liver metastases of colorectal cancer, but
was low or absent in normal colorectal epithelium, ade-
noma, and primary lesions [6]. Later, we and other several
groups provided strong evidence to show that PRL-3 is
overexpressed in diverse malignancies, including colorec-
tal, breast, gastric, and ovarian cancers, and its expression
is correlated with disease progression and survival [7-14].
A recent study by Molleví et al. demonstrated that tumor
microenvironment play a critical role in regulating PRL-3
expression[15]. To date, PRL-3 is not only thought as a
potential prognostic factor for diagnosis and survival of
multiple type cancers, but also has a therapeutic implica-
tion, because its expression at the invasive margin of
tumor predicted resistance to radiotherapy and unfavora-
ble survival for patients [16,17].
Previous studies also revealed that PRL-3 plays a causative
role in promoting cell motility, invasion, and metastasis
[18,19]. However, little is known about the molecular
mechanisms by which PRL-3 promotes motility, invasion
and metastasis. It was reported that PRL-3 exerted its func-
tions by regulating Rho family GTPase [20], activating Src
[21], and modulating PI3K-Akt pathway [22] in a context-
dependent manner. In addition, a transcriptional regula-
tion of PRL-3 by p53 has been reported [23]. In our previ-
ous study, we found a physical association between PRL-
3 and integrin α1 by yeast two-hybrid and GST-pull down
assays [24]. We also observed decreased tyrosine phos-
phorylation of integrin β1 and enhanced phosphoryla-
tion of extracellular signal-regulated kinase 1/2 (ERK1/2)
in exogenous PRL-3-stably expressing HEK293 cells.
Integrins is a large family of heterodimeric cell-surface
receptors and integrin-mediated extracellular signals stim-
ulate a variety of intracellular signaling events, including
tyrosine phosphorylation and mitogen-activated protein
kinase (MAPK) cascades, leading to the ERK activation,
which is involved in cell survival and proliferation, and
promotes metaplasia and tumor development [25-28].
Therefore, in the present study, we investigated the func-
tional roles of integrin signaling and ERK1/2 activation in
PRL-3-promoted motility, invasion, and metastasis in
colon cancer cell LoVo. We verified the enhancement of
ERK1/2 phosphorylation in PRL-3-stably expressing LoVo
(LoVo-P) cells. Knockdown of integrin β1 not only inhib-
ited PRL-3-induced ERK1/2 phosphorylation, but also
abrogated PRL-3-mediated motility, invasion, and lung
metastasis in nude mice. In the downstream of integrin β1
pathway, ERK1/2 phosphorylation and MMP2 activity
were found to be responsible for PRL-3-mediated cell
invasion. Collectively, our study demonstrated that the
integrin  β1-ERK1/2 and -MMP2 signaling plays critical
roles in PRL-3-promoted motility, invasion, and metasta-
sis of colon cancer cells.
Methods
Reagents and cell culture
We purchased anti-integrin β1 anitbody (MAB 1965)
from Chemicon (Temecula, CA). Anti-phosphorylated
tyrosine antibody 4G10 was from Millipore (Billerica,
MA). Monoclonal antibody 3B6 against PRL-3 was gener-
ated as previously described [29]. Polyclonal antibody to
PRL-3 was from Sigma. Antibodies against ERK1/2 and
phosphorylated ERK1/2 (p-ERK1/2) were from Upstate
(Beverly, MA). Anti-p53 antibody (DO-1) was from Santa
Cruz. U0126 was from Cell Signaling (Beverly, MA).
Colon cancer cell line LoVo (ATCC, Manassas, VA) were
maintained in Ham's F12K medium (Invitrogen) supple-
mented with 10% fetal calf serum.
Plasmids and transfection
Myc-tagged human PRL-3 cDNA was inserted into
pcDNA3.1 at BamH I/Xba I sites to generate a mammalian
expression plasmid pcDNA3.1-PRL-3. Then, pcDNA3.1-
PRL-3 and pcDNA3.1 were transfected into LoVo cells
with Lipofectamine 2000 (Invitrogen) to generate PRL-3-
stably expressing and control cells, respectively. After 4
weeks of selection with 600 μg/mL of Geneticin (Invitro-
gen), expression of PRL-3 was verified by RT-PCR and
Western blot. Plasmid pEGFP-C1-PRL-3 was generated by
ligating BamH I/EcoR I digested full-length PRL-3 to Bgl
II/EcoR I digested pEGFP-C1 vector (Clontech, Palo Alto,
CA).
RNA interference
Integrin β1-specific siRNA, synthesized by Sigma-Aldrich
Corporation (St. Louis, MO), was designed to silence all
splices of human integrin β1 mRNA. The sequence was:
sense, 5'-GGAAAUGGUGUUUGCAAGUdTdT-3'; anti-
sense, 5'-ACUUGCAAACACCAUUUCCdTdT-3'. It was
scrambled to generate a negative control. Lentivirus vec-
tors expressing short hair-pin (sh)RNA targeting PRL-3 or
integrin  β1 were constructed, packed, and purified byMolecular Cancer 2009, 8:110 http://www.molecular-cancer.com/content/8/1/110
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GeneChem Corporation (Shanghai, China), and was
manipulated according to the Biological Institutional
Committee of Beijing.
Western blot and immunoprecipitation
Cells were homogenized in lysis buffer (50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM DTT, 1 mM phe-
nylmethylsulfonyl fluoride, 10 mM NaF, 1 mM Na3VO4,
1 × protease cocktail) for 20 min at 4°C. The supernatant
was collected after centrifugation at 12,000 × g for 20 min
at 4°C and subjected to Western blot or immunoprecipi-
tation as previously described [24]. Documentation of
blots was performed by scanning with an EPSON PER-
FECTION 2580 scanner and acquired images were
adjusted by the Auto-Contrast command of Photoshop
CS (Adobe, San Jose, CA).
Immunohistochemical analysis
Consecutive 4-μm paraffin-embedded sections of colon
cancer tissues were obtained from the Department of
Pathology of the Beijing Cancer Hospital and Institute.
Staining of PRL-3 or p-ERK1/2 protein by an immunohis-
tochemical assay was performed as previously described
[7]. Specimens with more than 10% positive-staining can-
cer cells were classified as positive.
Motility and invasion assays
For transwell chamber-based motility and invasion
assays, equal amounts of cells were loaded into an insert
provided with serum-free medium and allowed to pass
through an 8-μm-pore polycarbonate filter, which had
been either pre-coated with 100 μg of Matrigel (Becton
Dickinson, San Jose, CA) for invasion assay or left
uncoated for motility assay. Medium supplemented with
10% fetal calf serum was added to the bottom chamber.
Cells on the upper surface of filters were wiped out after
24 h (motility assay) or 48 h (invasion assay), and those
on the undersurface were stained with 1% amino toluene
blue and counted under a microscope.
In vitro wound healing assay
Cells were seeded onto 6-well plates at a sub-confluent
density. After 12 h, a line was scrapped out on the cell
monolayer by a 200-μl pipet tip and the width of this
wound line was photographed using an inverted micro-
scope (ECLIPSE TS100, Nikon, Japan) at a 24 h interval.
The motility speed of cells was assessed by the healing
degree of the wound line. The experiment was repeated
three times independently.
Indirect immunofluorescence
To visualize green fluorescent protein (GFP) tagged PRL-
3, LoVo cells were transfected with pEGFP-C1-PRL-3 and
seeded onto coverslips. For indirect immunofluorescence
assays, pEGFP-C1-PRL-3 transiently transfected LoVo cells
were fixed with 4% paraformaldehyde for 10 min at room
temperature, permeabilized with 0.5% Triton X-100/
phosphate-buffered saline for 5 min, and blocked with
3% bovine serum albumin for 30 min. Anti-integrin β1
antibody was then added to the cells, followed with a
tetramethyl rhodamine isothiocyanate-conjugated sec-
ondary antibody. After washing with phosphate-buffered
saline/Tween-20, coverslips were mounted on glass slides
with 50% glycerol/phosphate-buffered saline and imaged
using a Leica SP2 confocal system (Leica Microsystems,
Dresden, Germany).
Metastasis study
We performed animal experiments in accordance with the
Experimental Animal Management Ordinance approved
by the Scientific and Technological Committee of China.
Every of the five experimental groups had eight 4 to 6-
week-old female nude BALB/c mice (Lian-Tong-Li-Hua
Corporation, Beijing, China). Each mouse was injected
via tail vein with 2.5 × 106 LoVo control (LoVo-C) or
LoVo-PRL-3 (LoVo-P) cells; the latter were pre-infected
with lentivirus interfering with PRL-3, integrin β1, or
mock control, respectively. Two months later, all animals
were sacrificed, and 4-μM paraffin-embedded sections of
lung and liver tissues were prepared. The sections were
stained with hematoxylin and eosin and examined for the
presence of metastatic tumor foci under a microscope.
Zymographic analysis
The zymographic analysis was adapted from Surgucheva
IG et al. [30]. Cells were grown to 70-80% confluence on
10-cm plates, washed twice with PBS, and cultured in
serum-free medium for another 36 h. Next, medium was
concentrated to one-tenth volume and measured for pro-
tein concentration. Appropriate volume of medium with
equivalent amount of protein was subjected to electro-
phoresis in 10% gel containing 0.1% gelatin. After electro-
phoresis, the gelatin gel was washed twice with 2.5%
Triton X-100 and allowed to perform an enzyme reaction
in Tris buffer (50 mM Tris-HCl at pH 7.4, 200 mM NaCl,
and 10 mM CaCl2) overnight at 37°C. Next, it was stained
with 0.5% Coomassie Brilliant Blue R-250 and de-stained
with 5% acetic acid containing 10% methanol.
Statistical analysis
Statistical analysis software package SPSS 12.0 (SPSS Inc.,
Chicago, IL) was used to perform Poisson distribution
events test and Chi-square test. P value less than 0.05 was
considered statistically significant.
Results
PRL-3 is associated with integrin  1
In a previous study, we found a physical interaction
between PRL-3 and integrin α1 [24]. As a membrane
receptor, integrin α1 can heterodimerize with differentMolecular Cancer 2009, 8:110 http://www.molecular-cancer.com/content/8/1/110
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members of integrin β family, including integrin β1, to
initiate signaling transduction. It is usually thought that
integrin α subunit is associated with ECM adhesion, while
β subunit is mainly responsible for signal transduction
[31]. To understand the functional relevance of the asso-
ciation between PRL-3 and integrin signaling, we firstly
transfected PRL-3 cDNA or vector control into human
colon cancer cell line LoVo, which has no detectable PRL-
3 protein expression even in the presence of genotoxic
stress by Adriamycin [see Additional file 1], which stabi-
lized p53, a known PRL-3 inducer at transcriptional level
[23]. After selection with Geneticin, stable expression of
Myc-tagged PRL-3 in LoVo-P cells was verified by Western
blot (Figure 1A) and RT-PCR (data not shown). Next, we
examined the interaction between PRL-3 and integrin β1
by immunoprecipitating PRL-3 with anti-Myc antibody,
followed by immunoblotting with anti-integrin β1.
Integrin β1 was observed in precipitates of LoVo-P cells
but not in that of LoVo-C cells (Figure 1A), indicating that
PRL-3 assocaited with integrin β1 in LoVo cells.
PRL-3 interacts with integrin β1 and decreases its tyrosine phosphorylation in LoVo cells Figure 1
PRL-3 interacts with integrin β1 and decreases its tyrosine phosphorylation in LoVo cells. (A) PRL-3 interacted 
with integrin β1. Equal amount of lysates (500 μg of protein) from LoVo-P cells, which stably expressed myc-tagged human 
PRL-3, and control LoVo-C cells were immunoprecipitated with anti-myc antibody, followed by Western blot with anti-integrin 
β1 antibody and anti-PRL-3 antibody. Expression of integrin β1 and PRL-3 in the lysates (50 μg of protein) was shown as Input. 
GAPDH protein expression was shown as a loading control. Molecular weight was shown. (B) PRL-3 was colocalized with 
integrin β1. LoVo cells were transiently transfected with GFP-PRL-3 (green). Twenty-four hours after transfection, cells were 
fixed, stained with an anti-integrin β1 antibody (red), and observed under a laser confocal microscope. The white arrow in 
Merge (4×) indicates the colocalization of PRL-3 with integrin β1 (yellow). (C) PRL-3 decreased tyrosine phosphorylated 
integrin β1. Equal amount of lysates (500 μg of preotein) from LoVo-C and LoVo-P cells were immunoprecipitated with anti-
phosphotyrosine antibody or IgG control. The precipitates were subjected to Western blot with anti-integrin β1.Molecular Cancer 2009, 8:110 http://www.molecular-cancer.com/content/8/1/110
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To better support this result, we examined subcellular
localization of transiently overexpressed GFP-tagged PRL-
3 and endogenous integrin β1 in LoVo cells by an indirect
immunofluorescence assay. Figure 1B showed that both
GFP-tagged PRL-3 and fluorescent antibody-labeled
integrin  β1 were expressed in cytoplasmic membrane.
Dual-color merged confocal imaging demonstrated that
PRL-3 was colocalized with integrin β1 (Figure 1B).
Previously, we noticed a decrease of integrin β1 tyrosine
phosphorylation in PRL-3-stably expressing HEK293 cells
[24]. Therefore, we checked the effect of PRL-3 on tyrosine
phosphorylation of integrin β1 in LoVo cells. Using equal
amount of lysates from LoVo-C and LoVo-P cells, we
immunoprecipiated tyrosine-phosphorlyated integrin β1
with a phospho-tyrosine specific antibody, respectively,
and immunoblotted it with anti-integrin β1 antibody.
Tyrosine-phosphorylated integrin β1 was found in both
cells, however, it was decreased in LoVo-P cells (Figure
1C), though integrin β1 protein expressed at similar level.
This result substantiated PRL-3's role in regulating tyro-
sine phosphorylation of integrin β1.
Integrin  1 is necessary for PRL-3-induced cell motility and 
invasion in vitro
Integrins are involved in diverse malignant phenotypes of
tumor, including invasion and metastasis [32]. PRL-3 is
also crucial for cancer cell motility, invasion, and metasta-
sis [18]. Considering the association between PRL-3 and
integrin β1 found above, we investigated the requirement
of integrin β1 for PRL-3-promoted cell motility and inva-
sion. To this end, cells were treated with a small interfer-
ing RNA (siRNA) against integrin β1 or a control siRNA.
After confirmation of silencing efficiency by RT-PCR and
Western blot (Figure 2A), migrating and invasive capaci-
ties of LoVo-C and LoVo-P cells were analyzed with tran-
swell chambers as described in Experimental Procedures.
Consistent with previous studies with other cancer cell
lines [18,19], PRL-3 enhanced LoVo cell motility and
invasion (Figure 2B). However, knockdown of integin β1
significantly impaired the migrating and invasive abilities
of LoVo-P cells (*, P < 0.05, Figure 2B and 2C), but not
those of LoVo-C cells. To further validate these results, we
performed wound healing assay. As shown in Additional
file 2, the speed of wound healing of LoVo-P cells was
faster than that of LoVo-C cells. By 72 h after wounding,
the wound of LoVo-P were almost closed up, while those
of LoVo-C cells were still wide apart. However integrin β1
inhibition substantially abolished the effect of PRL-3.
Integrin  1 is required for PRL-3-induced metastasis in vivo
Given the role of integrin β1 in mediating PRL-3's in vitro
effect on cell motility and invasion, we further examined
the requirement of integrin β1 for PRL-3-mediated metas-
tasis in nude mouse BALB/c, which are immunodeficient
and susceptible to tumor formation and metastasis. First,
lentivirus interfering with expression of PRL-3 or integrin
β1 was generated, respectively, and their silencing effi-
ciencies were verified by RT-PCR and Western Blot (Figure
3A). Next, LoVo-P cells were infected with control-, PRL-
3-, or integrin β1-interference lentivirus for 48 h. Then
each nude mouse was injected via tail vein with 2.5 × 106
LoVo-C or LoVo-P cells, which had been infected with len-
tivirus or not as listed in Table 1. Two months later, nude
mice were sacrificed and dissected. No macroscopic
tumors were found in all organs of the dissected mice
(data not shown). Livers and lungs were isolated, fixed
with formalin, and prepared for 4-μm paraffin-embedded
slices. The slices were stained with hematoxylin and eosin,
and subjected to microscopic observation for metastatic
foci. No metastatic tumor was found in livers of all groups
(data not shown), possibly due to minimally hepatophilic
property of LoVo cells. As shown in Table 1, 13 and 8 lung
metastatic foci were respectively found in uninfected
LoVo-P group and control-lentivirus infected LoVo-P
group, whereas none was found in LoVo-C group (*, P <
0.05). Though control-lentivirus infected LoVo-P group
formed less metastatic foci than uninfected LoVo-P group,
there was no statistical significance (P > 0.05). This differ-
ence might result from the side effects of lentivirus infec-
tion. However, there was only 1 metastatic tumor formed
in PRL-3-interference LoVo-P and integrin β1-interference
LoVo-P groups (*, P < 0.05, compared to control-lentivi-
rus LoVo-P group), respectively. The representative illus-
trations of hematoxylin and eosin staining were
demonstrated in Figure 3B. These results support that
integrin β1 is crucial for PRL-3-promoted metastasis in
vivo.
Integrin  1 is required for PRL-3-induced ERK1/2 activation
We previously found that overexpression of PRL-3 acti-
vated ERK1/2 in HEK293 cells [24]. We also obtained a
similar result in LoVo cells (Figure 4A). ERK is an impor-
tant signal transducer triggered by integrin and is closely
implicated in ECM-dependent cell motility [33-35]. To
examine the relevance of PRL-3 with ERK1/2 activity in
colon cancer, expression of PRL-3 and p-ERK1/2 in 11
pairs of consecutive 4-μm primary lesions from sporadic
colon cancer patients was evaluated by an immunohisto-
chemical assay with anti-PRL-3 and anti-p-ERK1/2 anti-
bodies, respectively. The representative staining of PRL-3
and p-ERK1/2 in tumor tissue slices is shown in Figure 4B.
We found 4 of 5 (90%) PRL-3-expressing samples simul-
taneously expressed p-ERK1/2, whereas 5 of 6 (83.3%)
PRL-3-negative samples were p-ERK1/2-negative either.
Statistic analysis (Chi-square test) showed that expression
of p-ERK1/2 was positively correlated with that of PRL-3
in colon cancer (see Additional file 3; *, P < 0.05). Inter-
estingly, knockdown of integrin β1 abolished PRL-3-
induced phosphorylation of ERK1/2 in LoVo-P cells (Fig-Molecular Cancer 2009, 8:110 http://www.molecular-cancer.com/content/8/1/110
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Integrin β1 mediates PRL-3-induced cell motility and invasion Figure 2
Integrin β1 mediates PRL-3-induced cell motility and invasion. (A) LoVo-P cells were treated with siRNA specific for 
integrin β1 or control. Seventy-two hours after transfection, cells were harvested. Equal amount of protein lysates (50 μg of 
protein) was analyzed for integrin β1 protein expression and RNA was extracted for RT-PCR. (B) and (C) Integrin β1 is 
required for PRL-3-induced cell motility and invasion. Cells were transfected with indicated siRNAs as in (A). Seventy-two 
hours after transfection, cells were analyzed for their motility and invasion with the use of transwell chambers. Cells were sus-
pended in serum-free medium and loaded at a density of 2.5 × 104 to an insert of a transwell chamber, and those migrating or 
invading to the underside of filtera were stained and counted after 24 h (B, motility assay) or 48 h (C, invasion assay). Top 
panel: Representative illustrations for motility and invasion assays (original magnification, × 200). Bottom panel: Quantification 
of migrating and invasive cells. Values were the total number of stained cells. The experiments were repeated at least three 
times independently. Error bars represent standard errors of the mean value (*, P < 0.05).Molecular Cancer 2009, 8:110 http://www.molecular-cancer.com/content/8/1/110
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ure 5A), raising the possibility that integrin β1 is an inter-
mediate transducer between PRL-3 and ERK1/2 signaling
pathway. Now that depletion of integrin β1 decreased
PRL-3-promoted cell motility and invasion and ERK1/2
activation (Figure 2B and 2C) but had no effect on protein
level of PRL-3 (Figure 5A), we sought to examine effects of
selective inhibition of ERK1/2 in the same cellular con-
text. LoVo cells were treated with 10 μM of the ERK1/2
inhibitor U0126, the concentration of which was suffi-
cient to abrogate ERK1/2 phosphorylation but neither the
protein levels of PRL-3 (Figure 5B) nor integrin β1 (data
not shown) in LoVo-P cells. We found that ERK1/2 inhi-
bition significantly reduced PRL-3-promoted motility and
invasion of LoVo-P cells (*, P < 0.05, Figure 5C, D), while
those of LoVo-C cells were not affected. Thus, we conclude
that ERK1/2 signaling is also crucial for functions of PRL-
3, and importantly, integrin β1 mediates the signaling
between PRL-3 and ERK1/2.
PRL-3 promotes cell invasion by altering the balance 
between MMP2 and TIMP2
We have shown that PRL-3 promoted invasion of LoVo
cells through integrin β1-mediated ERK1/2 signaling.
Invasion is a key process of cancer cell metastasis. It is
involved with secreting proteolytic enzymes, including
Matrix metalloproteinase (MMPs), to degrade ECM and
basement membranes. MMPs are capable of degrading all
components of ECM and play important roles in tumor
metastasis [36,37]. It was reported that MMPs could be
activated by integrin and ERK signaling [38-41]. There-
fore, we first examined the requirement of MMPs activity
for PRL-3-mediated invasion. LoVo-C and LoVo-P cells
Depletion of integrin β1 or PRL-3 abrogates PRL-3-promoted metastasis in vivo Figure 3
Depletion of integrin β1 or PRL-3 abrogates PRL-3-promoted metastasis in vivo. LoVo-P cells were infected with 
lentivirus interfering with PRL-3, integrin β1, or control respectively at a multiplicity of infection value of 100 for 48 h, or left 
untreated. (A) Validation of silencing efficiency of Lentivirus by RT-PCR and Western blot. (B) Each nude BALB/c mouse was 
injected via the tail vein with 2.5 × 106 LoVo-C or LoVo-P cells. Two months later, mice were sacrificed, and 4-μm paraffin 
slices of liver and lung tissues were stained with hematoxylin and eosin dyes and examined under a light microscope. Arrows 
indicate the presence of a metastatic tumor in a lung slice.Molecular Cancer 2009, 8:110 http://www.molecular-cancer.com/content/8/1/110
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were treated with the MMPs inhibitor GM6001 and ana-
lyzed for invasion abilities with transwell chambers. Fig-
ure 6A showed that GM6001 significantly reduced PRL-3-
induced invasion in LoVo-P (*, P < 0.05), but not in
LoVo-C, supporting a functional link between PRL-3 and
MMPs activity.
To dissect the mechanism of MMPs in PRL-3-promoted
cell invasion, gelatinolytic activities of MMP2 and MMP9,
two key members of MMP family, were examined by a
zymographic assay. In brief, concentrated and normalized
serum-free medium of LoVo-C and LoVo-P cells, which
contained MMPs secreted by cells, were subjected to elec-
trophoresis in a 10% gel containing the substrate of gela-
tin and carried out enzymatic reaction. Bright bands
contrasting to dark background indicated the absence of
gelatin, which had been hydrolyzed by MMPs running to
the corresponding molecular weight. Figure 6B showed
that MMP2 activity was strongly increased in the culture
medium of LoVo-P cells compared to that of LoVo-C cells.
No activity of MMP9 was detected in these cells. It is
known that activity of MMP2 is regulated by a dynamic
balance between MMP2 and its endogenous tissue inhib-
itor TIMP2 post-translationally [42,43]. To clarify whether
increased MMP2 activity resulted from up-regulation of
MMP2 or down-regulation of TIMP2, we examined
expression of MMP2 and TIMP2 at both mRNA and pro-
tein levels in LoVo-C and LoVo-P cells. MMP2 mRNA was
Table 1: Metastasis of LoVo-C and LoVo-P Cells in Nude Mice BALB/c
Group Total number of mice Number of mice with metastasis Number of metastatic foci
LoVo-C uninfected 8 0 0 *
LoVo-P uninfected 8 4 13
LoVo-P lentivirus-control 8 4 8
LoVo-P lentivirus-integrin β18 1 1  *
LoVo-P lentivirus-PRL-3 8 1 1 *
*P < 0.05 when compared to LoVo-P lentivirus-control
Statistical analysis was performed with Poisson distribution events test
Correlation between PRL-3 level and ERK phosphorylation Figure 4
Correlation between PRL-3 level and ERK phosphorylation. (A) PRL-3 enhanced ERK1/2 phosphorylation in LoVo 
cells. Equal numbers of LoVo-C and LovO-P cells were cultured for 24 h with complete medium. Cells were harvested and 
lyzed. Then cell lysates (50 μg of protein) were subjected to Western blot with antibodies against p-ERK1/2, ERK1/2, Myc-tag 
(for Myc-PRL-3), integrin β1, and GAPDH, respectively. (B) Expression of PRL-3 and p-ERK1/2 in primary lesions of human 
colon cancer tissues was analyzed by an immunohistochemical assay. Two consecutive 4-μm paraffin-embedded slices of the 
same tissue sample were probed with anti-PRL-3 (a, c, e, g) and anti-p-ERK1/2 (b, d, f, h), respectively. The representative neg-
ative staining of PRL-3 and p-ERK1/2 in the consecutive slices was shown in a and b, and the representative positive staining of 
PRL-3 and p-ERK1/2 was shown in the c, d, e, f, g, h (c and d, without HE counterstaining; e, f, g, h, with HE counterstaining; g 
and h, enlarged views of e and f, respectively).Molecular Cancer 2009, 8:110 http://www.molecular-cancer.com/content/8/1/110
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Integrin β1 mediates PRL-3-induced ERK1/2 activation Figure 5
Integrin β1 mediates PRL-3-induced ERK1/2 activation. (A) Knockdown of integrin β1 abolished PRL-3-induced ERK1/
2 phosporylation. LoVo-P cells were treated with siRNA against integrin β1 or control for 72 h, and then lysates (50 μg of pro-
tein) were subjected to Western blot to analyze the expression of p-ERK1/2, ERK1/2, Myc-tag (for Myc-PRL-3), integrin β1, 
and β-actin (B) U0126 inhibited PRL-3-induced ERK1/2 phosporylation in a dose-dependent manner. Twenty-four hours after 
plating, LoVo-C and LoVo-P cells were treated with indicated concentration of U0126 for 1 h, and their lysates (50 μg of pro-
tein) were analyzed for p-ERK1/2, ERK1/2 and Myc-tag (for Myc-PRL-3) by Western blot. (C) and (D) Inhibition of ERK1/2 
activity by U0126 abolished PRL-3-induced cell motility and invasion. LoVo-C and LoVo-P cells were treated with 10 μM of 
U0126 for 1 h, and then subjected to motility and invasion assays as described in Figure 2B and 2C, respectively. Values were 
the total number of stained cells. The experiments were repeated at least three times independently. Error bars represent 
standard errors of the mean value (*, P < 0.05).Molecular Cancer 2009, 8:110 http://www.molecular-cancer.com/content/8/1/110
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increased in LoVo-P cells, contrary to the decrease of
TIMP2 mRNA in LoVo-P cells (Figure 6C, left). At protein
level, MMP2 was decreased and TIMP2 were hardly
detected in LoVo-P cells (Figure 6C, right). We reasoned
that the decrease of MMP2 protein level of LoVo-P cell
lysates might result from enhanced secretion of activated
MMP2 into the outside of cells or increase of activation-
induced MMP2 proteolysis. Therefore, PRL-3 might alter
the balance between MMP2 and TIMP2 to facilitate
MMP2 activation at multiple levels.
Discussion
Protein kinases and phosphatases regulate multiple phys-
iological processes [44,45]. Phosphatases usually function
as tumor suppressors, but some of them have stimulatory
effects on cancer-associated processes[46]. PRL-3 is a
metastasis-promoting phosphatase [47,48]. It has been
found to promote metastasis of a variety of cells, includ-
ing Chinese hamster ovary cell CHO, mouse melanoma
cell B16, and gastric cancer cell SGC7901 [18,19,49].
In this study, we examined the roles of integrin β1-ERK1/
2 signaling in PRL-3-facilitating metastasis using human
colon cancer cell LoVo, colon cancer tissues from patients,
and a metastatic mouse model. We found endogenous
integrin β1 was associated and colocalized with exoge-
nous PRL-3 in LoVo cells. We tried to explore whether
there is a direct interaction between these two molecules
by an in vitro binding assay with purified recombinant
PRL-3 and cytoplasmic domain of integrin β1, however,
no interaction was found (data not shown). It's possible
that integrin α1 mediated PRL-3-integrin β1 interaction,
because we previously showed that PRL-3 physically inter-
acted with integrin α1 in HEK293 cells [24]. Unfortu-
nately, integrin α1 protein was not detected in LoVo cells.
Whereas in both LoVo-P cells and gastric cancer cells
BGC823 stably expressing PRL-3 (BGC823-P), which have
detectable integrin α1 on the cell membrane, we observed
PRL-3-integrin β1 interaction (data not shown), suggest-
ing that such interaction might be indirect and integrin
α1-independent, at least for these two cell lines. Besides
α1, integrin α2-9 and α V are also integrin β1-binding
proteins [33]. Their roles in mediating the PRL-3-integrin
β1 interaction deserve further exploration.
Here we demonstrated that stable expression of PRL-3
decreased tyrosine phosphorylation of integrin β1. Tyro-
sine phosphorylation of integrin β1 has been reported to
impair its binding ability with talin [50]. Another study
showed that tyrosine dephosphorylation of integrin β1
altered its association with actin [51]. Recently, a large-
scale survey of tyrosine kinase activity in non-small cell
lung cancer cell lines identified Y783 of integrin β1 as a
potential phosphorylation site [52]. However, kinases
and phosphatase responsible for tyrosine phoshorylation
modification of integrin β1 are unknown. Therefore, it
remains to be determined whether phosphorylation mod-
ification of integrin β1 is critical for its signaling transduc-
tion and necessary for functions of PRL-3 or whether
integrin β1 is a substrate of PRL-3.
We also revealed a PRL-3-integrin β1-ERK1/2 pathway in
controlling motility and invasion of colon cancer cell
LoVo. We showed that both activation of ERK1/2 and the
presence of integrin β1 were necessary for PRL-3 to pro-
mote motility and invasion. Activation of ERK1/2 by PRL-
3 is dependent on integrin β1. Moreover, knockdown of
integrin  β1 efficiently inhibited PRL-3-mediated lung
metastasis of LoVo cells in nude mice with a comparable
effect to that of silencing of PRL-3. However, the interme-
diate signaling events between integrin β1 and ERK1/2 are
still unclear. Activation of ERK is stimulated by both solu-
ble growth factors and integrin-mediated adhesion sig-
nals. Integrins intersecting the ERK/MAPK pathway at
multiple level, and the crosstalk between growth factors
and integrin signaling, give rise to complicated integrin
signaling networks and distinctive ERK activation signals
[53-55]. To find the intersection point of PRL-3 in the
integrin signaling networks would contribute to clarifying
the PRL-3 promoted motility, invasion and metastasis.
Interestingly, PRL-3 has been reported to activate Src
kinase to initiate signaling events, culminating in path-
ways of ERK1/2, Stat3, and p130cas [21]. Src is one of
downstream factors of integrin β1 signaling as well as a
upstream molecule of ERK activation [56]. Therefore,
whether PRL-3 activates ERK1/2 through the integrin β1-
Src pathway or others, such as the integrin β1-Grb2 path-
way, deserves further exploration. Downstream of the
PRL-3-integrin β1-ERK1/2 pathway, we found that MMP2
exerted proteolysis function on ECM, a critical event for
cancer metastasis. PRL-3 enhanced gelatin hydrolytic
activity of MMP2 by increasing MMP2 mRNA and
decreasing TIMP2 mRNA and protein. The imbalance of
MMP2/TIMP2 expression might account for high MMP2
enzymatic activity imposed by PRL-3 overexpression. In a
recent study, PRL-3 expression level was found to be pos-
itively correlated with MMP2 activity in high grade of gli-
oma tissues [57], supporting our findings about MMP2
activation in LoVo cells. The precise mechanism of PRL-3
in regulating MMP2 remains to be further clarified.
Conclusion
Taken together, our results suggest that PRL-3's roles in
motility, invasion, and metastasis in colon cancer are crit-
ically controlled by the integrin β1-ERK1/2-MMP2 signal-
ings. Deeper dissecting the regulation of the PRL-3-
integrin β1-ERK1/2-MMP2 pathway may have a therapeu-
tic implication for prognosis and treatment for colon can-
cer metastasis.Molecular Cancer 2009, 8:110 http://www.molecular-cancer.com/content/8/1/110
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